In the SURPASS trials, tirzepatide at its highest dose (15 mg weekly) reduced A1C by approximately 2.4%, with average weight losses exceeding 12 kg
GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials
Adlyxin (lixisenatide)
New delivery routes including sublingual, intranasal, and inhaled formulations have attracted patent interest [9, 33, 34] and some scientific attention [35], though market signals remain limited
When people lose weight quickly, they may lose a mix of fat, water, and lean mass
GLP-1 Medication Semaglutide is a GLP-1 medication that mimics the hormone that tells the brain its finished eating, suppressing hunger and decreasing appetite